PRA, a clinical research organization (CRO), today announced the official opening of its new facility in Swansea, Wales. The new building, located on the Swansea waterfront, is a significant investment for PRA in Wales. The company is expanding its Clinical Informatics team in Swansea by establishing a new multi-lingual Help Desk, creating more positions in the Data Coordination, Clinical Programming, and Safety groups. It is planned that the expansion will create 100 new graduate-level jobs. PRA is keen to recruit high quality graduates from Swansea, Cardiff and Aberystwyth Universities and the University of South Wales, for a range of jobs from programmers to data managers.
PRA’s new Welsh home office was officially opened today by Edwina Hart AM MBE OStJ, Minister for the Economy, Science and Transport, who announced the expansion is being supported with £1.29 million business finance from the Welsh Government.
“A number of other locations were under consideration for this important expansion project so I am delighted that support from the Welsh Government helped secure it for Wales,” said Mrs. Hart. “This investment is particularly welcome as PRA is a strategically important company within the Life Sciences sector – one of our priority economic sectors with high growth potential.” She added that the expansion will create a significant number of highly-skilled jobs across a range of disciplines over the next three years and reaffirms PRA’s commitment to Wales.
Steve Powell, PRA Executive Vice President, Clinical Informatics and Late Phase Services, said, “We are delighted to officially open our expanded location in Swansea. The new site has received substantial funding from the Welsh government which will mean significant job creation and support for the local economy. As a leading CRO, we are committed to the growth of our Swansea team and to transforming clinical trials across all phases of drug development; the new building and jobs demonstrates PRA’s commitment to offering a more dynamic service to our customers, both locally and internationally.”
PRA, headquartered in North Carolina in the United States, currently employs more than 5,000 employees in over 50 global offices, with the Swansea operation currently providing 100 Clinical Informatics and administration staff who collect, analyze and interpret data from clinical trials. The planned expansion will double the size of the office and ultimately employ close to 200 people in the Swansea area.
Formerly based in Matrix Court, Swansea, PRA moved to Llys Tawe on Swansea’s SA1 development. The move supports PRA's key strategic objective of creating seamless logistics from data collection through information submission for its global customer base.
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
FDA-Approved Gene Therapy Beqvez Shows Sustained Efficacy, Safety in Long-Term Hemophilia B Trial
April 17th 2025Beqvez (fidanacogene elaparvovec), an FDA-approved one-time gene therapy for hemophilia B, demonstrated sustained factor IX expression, low bleeding rates, and a favorable safety profile over long-term follow-up.